|
Mutation Information
|
Mutation Site
|
M550V |
|
Mutation Type
|
Amino acid level |
|
Gene/Protein/Region Type
|
P |
|
Combined Mutation
|
p.M550V+p.L526M |
|
Relevant Drug
|
lamivudine (LAM) |
Literature Information
|
PubMed PMID
|
14742682
|
|
Published Year
|
2004 |
|
Journal
|
Molecular pharmacology |
|
Title
|
Reverse transcriptase activity of hepatitis B virus (HBV) DNA polymerase within core capsid: interaction with deoxynucleoside triphosphates and anti-HBV L-deoxynucleoside analog triphosphates. |
|
Author
|
Lam W,Li Y,Liou JY,Dutschman GE,Cheng YC |
|
Evidence
|
The use of L(-)SddC [beta-L-2',3'-dideoxy-3'-thiacytidine (lamivudine, 3TC)] for the treatment of Herpes B virus (HBV) infection is hindered by the emergence of drug-resistance associated with the L526M, L550V, and L526M/M550V mutations of the viral DNA polymerase (DP).
|
|
|
HBV Mutation Detail Information